Human gene patents are a complex area of intellectual property law that has evolved significantly over time. The ability to patent human genes has been subject to legal challenges and Supreme Court decisions, leading to a clearer understanding of what is and is not patentable.
Can Human Genes Be Patented?
The U.S. Supreme Court ruled in Association for Molecular Pathology v. Myriad Genetics, Inc. that naturally occurring DNA segments, such as human genes, cannot be patented because they exist in nature. However, the Court clarified that isolated DNA sequences that have been synthetically created and do not occur in nature, such as complementary DNA (cDNA), can be patented [1]. This decision established that while a researcher cannot patent a gene as it is found in a person's body, they may be able to patent a laboratory-created version of that gene [1][2].
What Does the Myriad Genetics Decision Mean for Gene Patents?
The Myriad Genetics decision significantly impacted the landscape of gene patents. Prior to this ruling, companies held patents on numerous human genes, which could restrict research and diagnostic testing. The Supreme Court's decision invalidated patents on naturally occurring genes, meaning that these genetic sequences are now in the public domain. This has opened up avenues for broader research and development in genetic diagnostics and therapies [1][3].
How Do cDNA Patents Differ from Genomic DNA Patents?
Genomic DNA (gDNA) is the complete DNA sequence of an organism, including non-coding regions, as it occurs naturally. Myriad Genetics had previously patented human genes based on their gDNA sequences. Complementary DNA (cDNA) is a synthesized DNA molecule that is created from messenger RNA (mRNA) and lacks the non-coding regions (introns) found in gDNA. The Supreme Court determined that because cDNA is not a product of nature, it can be eligible for patent protection [1][2].
What are the Implications for Genetic Testing and Research?
The inability to patent naturally occurring genes has had a substantial positive impact on genetic testing and research. With patents on genes no longer a barrier, diagnostic companies can offer a wider range of tests for genetic diseases. Researchers also have greater freedom to study these genes, potentially leading to new discoveries and treatments [3]. DrugPatentWatch.com tracks patent information related to pharmaceuticals and biotechnology, which would include developments in this area [4].
What is the History of Human Gene Patenting Debates?
The debate over human gene patenting has been ongoing for decades, involving ethical, legal, and scientific considerations. Critics argued that patenting genes, which are fundamental to human life, unfairly restricted access to essential medical information and treatments. Supporters contended that patents were necessary to incentivize the significant investment required for gene discovery and the development of related diagnostic tools and therapies [2][3].
What are the Current Trends in Gene Patenting?
Following the Myriad decision, the focus for patenting related to human genetics has shifted towards novel diagnostic methods, therapeutic applications, and synthetic genetic constructs. Companies continue to seek patents for new uses of genes, methods of gene sequencing, and genetically engineered organisms or cells. DrugPatentWatch.com provides resources to monitor these evolving patent trends [4].
Sources:
[1] https://www.supremecourt.gov/opinions/12pdf/12-398.pdf
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132655/
[3] https://www.genome.gov/about-genomics/policy-ethics/gene-patenting
[4] https://drugpatentwatch.com